85/100 · Critical
Manufactured by Fresenius Kabi USA, LLC
Fludarabine Phosphate Adverse Events: High Seriousness and Diverse Reactions
79,367 FDA adverse event reports analyzed
Last updated: 2026-05-12
FLUDARABINE PHOSPHATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Fresenius Kabi USA, LLC. Based on analysis of 79,367 FDA adverse event reports, FLUDARABINE PHOSPHATE has a safety score of 85 out of 100. This score indicates a relatively favorable safety profile, with fewer or less severe adverse events compared to many other tracked medications. The most commonly reported adverse reactions for FLUDARABINE PHOSPHATE include OFF LABEL USE, PYREXIA, DRUG INEFFECTIVE, CYTOKINE RELEASE SYNDROME, FEBRILE NEUTROPENIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for FLUDARABINE PHOSPHATE.
Fludarabine Phosphate has a safety concern score of 85 out of 100, placing it in the high concern category based on analysis of FDA adverse event data. The FDA has received approximately 79,367 adverse event reports for this medication, which is primarily manufactured by Fresenius Kabi Usa, Llc.
The most commonly reported adverse events include Off Label Use, Pyrexia, Drug Ineffective. Of classified reports, 97.7% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. High percentage of serious adverse events (97.7%) indicates significant risk.
Diverse range of reactions, including severe infections and hematological issues. Common reactions include febrile neutropenia, pneumonia, and cytokine release syndrome.
Patients taking Fludarabine Phosphate should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Fludarabine Phosphate can cause severe infections and hematological issues, and may interact with other immunosuppressive drugs, necessitating careful monitoring. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Fludarabine Phosphate received a safety concern score of 85/100 (high concern). This is based on a 97.7% serious event ratio across 37,592 classified reports. The score accounts for 79,367 total adverse event reports and 100 distinct reaction types. This high score reflects a significant proportion of serious adverse events in the reporting data.
Adverse event reports by sex: Male: 17,123, Female: 11,454, Unknown: 629. The most frequently reported age groups are age 65 (684 reports), age 64 (653 reports), age 59 (597 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 37,592 classified reports for FLUDARABINE PHOSPHATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
Fludarabine Phosphate can cause severe infections and hematological issues, and may interact with other immunosuppressive drugs, necessitating careful monitoring.
If you are taking Fludarabine Phosphate, here are important things to know. The most commonly reported side effects include off label use, pyrexia, drug ineffective, cytokine release syndrome, febrile neutropenia. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Patients should be closely monitored for signs of severe infections and hematological issues. Healthcare providers should be aware of the potential for cytokine release syndrome and graft-versus-host disease. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
The FDA closely monitors adverse events for Fludarabine Phosphate, and healthcare providers should report any serious adverse events promptly.
The FDA has received approximately 79,367 adverse event reports associated with Fludarabine Phosphate. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Fludarabine Phosphate include Off Label Use, Pyrexia, Drug Ineffective, Cytokine Release Syndrome, Febrile Neutropenia. By volume, the top reported reactions are: Off Label Use (4,055 reports), Pyrexia (2,873 reports), Drug Ineffective (2,846 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Fludarabine Phosphate.
Out of 37,592 classified reports, 36,735 (97.7%) were classified as serious and 857 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Fludarabine Phosphate break down by patient sex as follows: Male: 17,123, Female: 11,454, Unknown: 629. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Fludarabine Phosphate adverse events are: age 65: 684 reports, age 64: 653 reports, age 59: 597 reports, age 58: 583 reports, age 60: 554 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Fludarabine Phosphate adverse event reports is Fresenius Kabi Usa, Llc. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Fludarabine Phosphate include: Product Use In Unapproved Indication, Neutropenia, Cytomegalovirus Infection, Thrombocytopenia, Sepsis. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Fludarabine Phosphate to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Fludarabine Phosphate has a safety concern score of 85 out of 100 (high concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. High percentage of serious adverse events (97.7%) indicates significant risk.
Key safety signals identified in Fludarabine Phosphate's adverse event data include: Severe infections (febrile neutropenia, pneumonia, sepsis) are frequent.. Hematological issues (neutropenia, thrombocytopenia, pancytopenia) are common.. Cytokine release syndrome and graft-versus-host disease are significant safety signals.. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Fludarabine Phosphate can cause severe infections and hematological issues, and may interact with other immunosuppressive drugs, necessitating careful monitoring. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Fludarabine Phosphate.
Patients should be closely monitored for signs of severe infections and hematological issues. Healthcare providers should be aware of the potential for cytokine release syndrome and graft-versus-host disease.
Fludarabine Phosphate has 79,367 adverse event reports on file with the FDA. Diverse range of reactions, including severe infections and hematological issues. The volume of reports for Fludarabine Phosphate reflects both the drug's usage level and the vigilance of the reporting community.
The FDA closely monitors adverse events for Fludarabine Phosphate, and healthcare providers should report any serious adverse events promptly. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.
Explore other medications manufactured by Fresenius Kabi USA, LLC and compare their safety profiles:
The following drugs share commonly reported adverse reactions with FLUDARABINE PHOSPHATE:
Drugs related to FLUDARABINE PHOSPHATE based on therapeutic use, drug class, or shared indications: